Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kissei Returns Marketing Right for Cinalong to UCB
March 1, 2010
- Toyama Chemical Initiates PII Trial for T-705 in the US
March 1, 2010
- Maruho to Market Actosin from April
March 1, 2010
- Nippon Shinyaku, Actelion to Codevelop Macitentan for PAH
March 1, 2010
- Takashi Kodama to Be Reelected JPA President
March 1, 2010
- Medipal Ties Up with Medical Ikkou
March 1, 2010
- Dr Hakui Elected as President of Osaka Medical Association
March 1, 2010
- DSP Aims at Increasing Overseas Sales to 50% of Total Sales in FY2014
March 1, 2010
- FDA Approves Crestor for Preventive Purposes: AZ
March 1, 2010
- Korosho Asks Local Governments to Increase Stock of Relenza
March 1, 2010
- Promoting Oncology Products with Small Number of Elite MRs: Dr Adachi of Eli Lilly
March 1, 2010
- Tykerb Approved for Use in Combination with Femara: GSK
March 1, 2010
- 1st Death Linked with New-Type Flu Vaccination Reported
March 1, 2010
- Chugai Licenses RG3616 from Roche
March 1, 2010
- Merci Retriever Recommended for Approval
March 1, 2010
- MTPC to Place Top Priority on Safety in Promoting Remicade for Psoriasis
March 1, 2010
- ICH Q4B Annexes Become Applicable in Japan
March 1, 2010
- UMN Pharma Seeks Marketing Partner for Its Flu Vaccines
March 1, 2010
- Pharma Industry Strives to Strengthen Ties with DPJ
March 1, 2010
- Abbott Completes Acquisition of Solvay Pharmaceuticals
March 1, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…